[go: up one dir, main page]

WO2009007348A3 - Use of antagonists of g protein coupled receptors (gpcrs) for treating diseases caused by agonistic autoantibodies activated gpcrs - Google Patents

Use of antagonists of g protein coupled receptors (gpcrs) for treating diseases caused by agonistic autoantibodies activated gpcrs Download PDF

Info

Publication number
WO2009007348A3
WO2009007348A3 PCT/EP2008/058802 EP2008058802W WO2009007348A3 WO 2009007348 A3 WO2009007348 A3 WO 2009007348A3 EP 2008058802 W EP2008058802 W EP 2008058802W WO 2009007348 A3 WO2009007348 A3 WO 2009007348A3
Authority
WO
WIPO (PCT)
Prior art keywords
gpcrs
antagonists
diseases caused
protein coupled
coupled receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/058802
Other languages
French (fr)
Other versions
WO2009007348A2 (en
Inventor
Rudolf Kunze
Marion Bimmler
Petra Hempel
Bernd Lemke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
E R D E AAK DIAGNOSTIK GmbH
Original Assignee
E R D E AAK DIAGNOSTIK GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by E R D E AAK DIAGNOSTIK GmbH filed Critical E R D E AAK DIAGNOSTIK GmbH
Publication of WO2009007348A2 publication Critical patent/WO2009007348A2/en
Publication of WO2009007348A3 publication Critical patent/WO2009007348A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Use of antagonists of G protein coupled receptors (GPCRs) for the preparation of a medicament for treating and preventing diseases caused by or associated with agonistic autoantibodies (agAABs) activated GPCRs.
PCT/EP2008/058802 2007-07-06 2008-07-07 Use of antagonists of g protein coupled receptors (gpcrs) for treating diseases caused by agonistic autoantibodies activated gpcrs Ceased WO2009007348A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07111956.4 2007-07-06
EP07111956A EP2011515A1 (en) 2007-07-06 2007-07-06 Verwendung von Antagonisten von G Protein gekoppelten Rezeptoren (GPCRs)

Publications (2)

Publication Number Publication Date
WO2009007348A2 WO2009007348A2 (en) 2009-01-15
WO2009007348A3 true WO2009007348A3 (en) 2009-03-19

Family

ID=38326867

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/058802 Ceased WO2009007348A2 (en) 2007-07-06 2008-07-07 Use of antagonists of g protein coupled receptors (gpcrs) for treating diseases caused by agonistic autoantibodies activated gpcrs

Country Status (2)

Country Link
EP (1) EP2011515A1 (en)
WO (1) WO2009007348A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021142253A1 (en) * 2020-01-10 2021-07-15 President And Fellows Of Harvard College Anti-angiotensin ii type 1 receptor (agtr1) binding proteins

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3920369A1 (en) * 1989-06-22 1991-01-10 Merck Patent Gmbh Pharmaceutical for preventing and treating migraine - contains 1-(P-2-isopropoxy:ethoxy:methyl-phenoxy)-3-isopropyl amino-propanol
TW206962B (en) * 1992-05-15 1993-06-01 Ind Tech Res Inst A novel production method of the atenolol - an anti-high-blood-pressure drug
US20060105044A1 (en) * 2004-05-20 2006-05-18 Singh Bramah N Sustained release formulations of sotalol
US20060231109A1 (en) * 2004-12-20 2006-10-19 Howell Thomas A Personal and portable bottle

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3920369A1 (en) * 1989-06-22 1991-01-10 Merck Patent Gmbh Pharmaceutical for preventing and treating migraine - contains 1-(P-2-isopropoxy:ethoxy:methyl-phenoxy)-3-isopropyl amino-propanol
TW206962B (en) * 1992-05-15 1993-06-01 Ind Tech Res Inst A novel production method of the atenolol - an anti-high-blood-pressure drug
US20060105044A1 (en) * 2004-05-20 2006-05-18 Singh Bramah N Sustained release formulations of sotalol
US20060231109A1 (en) * 2004-12-20 2006-10-19 Howell Thomas A Personal and portable bottle

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
[HEART INSUFFICIENCY: CAUSE, PATHOPHYSIOLOGY, AND THERAPY] WISSENSCHAFTLICHE VERLAGSGESELLSCHAFT MBH {A}, BIRKENWALDSTRASSE 44, D-7000 STUTTGART, GERMANY, 1995, pages 245 - 250, ISSN: 3-8047-1405-6 *
BRODDE O E ET AL: "Bedeutung von ß2-Adrenorezeptoren bei Herzinsuffizienz", ZEITSCHRIFT FÜR KARDIOLOGIE, vol. 81, no. Suppl.4, 1992, pages 71 - 78, XP009088075 *
CHUGH S S ET AL: "Amplified effects of d,l-sotalol in canine dilated cardiomyopathy", JOURNAL OF PACING AND CLINICAL ELECTROPHYSIOLOGY, vol. 24, no. 12, 2001, pages 1783 - 1788, XP002446304 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1991, HASHIMOTO H ET AL: "FEATURES OF THE ACUTE HYPOTENSIVE ACTION OF CARVEDILOL AND ITS AMELIORATING EFFECT ON MYOCARDIAL ISCHEMIA", XP002446309, Database accession no. PREV199293020608 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1995, ERDMANN E: "Treatment of chronic heart insufficiency with beta receptor blockers", XP002446308, Database accession no. PREV199698615530 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 2004, KALUS J S ET AL: "Nebivolol: A beta antagonist with novel pharmacologic properties", XP002446310, Database accession no. EMB-2004505134 *
FORMULARY 2004 UNITED STATES, vol. 39, no. 11, 2004, pages 532 - 541, ISSN: 1082-801X *
IWATA MICHIKADO ET AL: "Autoimmunity against the second extracellular loop of beta1-adrenergic receptors induces beta-adrenergic receptor desensitization and myocardial hypertrophy in vivo", CIRCULATION RESEARCH, vol. 88, no. 6, 30 March 2001 (2001-03-30), pages 578 - 586, XP002495272, ISSN: 0009-7330 *
JAHNS R ET AL: "A NEW CYCLIC RECEPTOR-PEPTIDE PREVENTS DEVELOPMENT OF HEART DILATATION AND FAILURE INDUCED BY ANTIBODIES ACTIVATING CARDIAC .BETA.1-ADRENERGIC RECEPTORS", CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, vol. 112, no. 17, SUPPL. S, 1 October 2005 (2005-10-01), pages U53,ABSTRACT120, XP009072196, ISSN: 0009-7322 *
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, vol. 18, no. SUPPL. 4, 1991, pages S22 - S28, ISSN: 0160-2446 *
MATSUI S ET AL: "Prevention of experimental autoimmune cardiomyopathy in rabbits by receptor blockers.", AUTOIMMUNITY 2001, vol. 34, no. 3, 2001, pages 217 - 220, XP009105530, ISSN: 0891-6934 *
SILKE B ET AL: "Comparative haemodynamic response-dose effects of intraveneous propanolol and pindolol in patients with coronary heart disease", EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, vol. 25, no. 2, 1983, pages 157 - 165, XP009088063 *
STRENG A ET AL: "Effectiveness and tolerability of acupuncture compared with metoprolol in migraine prophylaxis", HEADACHE, vol. 46, no. 10, 2006, pages 1492 - 1502, XP002446303 *
WALLUKAT ET AL: "Possible pathogenic role of beta1-adrenoceptor autoantibodies in peripartum cardiomyopathy", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, XX, XX, vol. 42, no. 6, 25 May 2007 (2007-05-25), pages S26 - S27, XP022091003, ISSN: 0022-2828 *

Also Published As

Publication number Publication date
EP2011515A1 (en) 2009-01-07
WO2009007348A2 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
WO2009137843A9 (en) Nmda receptor antagonists for the treatment of neuropsychiatric disorders
WO2010008831A3 (en) Compounds and methods for modulating g protein-coupled receptors
PL1729753T3 (en) Use of an nmda receptor antagonist for the treatment of tinnitus induced by cochlear excitotoxicity
MX2009006304A (en) Novel oxadiazole compounds.
EP2006380A4 (en) Agonistic antibody directed against human thrombopoietin receptor
WO2006015259A3 (en) Compounds and compositions as modulators of steroid hormone nuclear receptors
EP2379594B8 (en) Human cgrp receptor binding antibodies
IL218228B (en) Use of an anti-calcitonin gene-related peptide (cgrp) antagonist antibody for the preparation of a medicament for treating visceral pain
EP2077810A4 (en) Ophthalmic injection device including dosage control device
WO2010043566A3 (en) Combination of an insulin and a glp-1 agonist
WO2010141768A3 (en) Polycyclic antagonists of lysophosphatidic acid receptors
IL207439B (en) Use of an anti-calcitonin gene-related peptide (cgrp) antagonist antibody for the manufacture of a medicament for the prevention and/or treatment of arthritic pain
WO2010077883A3 (en) Antagonists of lysophosphatidic acid receptors
WO2007114926A3 (en) Kinase antagonists
WO2010039977A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
IL193604A (en) Use of antibodies against human il-22 for the manufacture of medicaments
PL1951661T3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2007108936A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists
PL1951658T3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
IL194773A (en) Use of an antisecretory protein for the manufacture of a pharmaceutical composition for the treatment of intraocular hypertension
IL193069A0 (en) Methods for treating unwanted weight loss or eating disorders by administering a trkb agonist
CL2007002643A1 (en) COMPOUNDS DERIVED FROM 5-PHENYL-NICOTINAMIDE, CB1 RECEIVER MODULATORS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITIONS; AND USE FOR THE TREATMENT AND / OR PROFILAXIS OF NUTRITION DISORDERS, TYPE II DIABETES AND DEPENDENCE OF SUSTAN
CL2007003483A1 (en) COMPOUNDS DERIVED FROM INDOL-2-IL-CARBONIL-ESPIRO-PIPERIDINA, ANTAGONISTS OF THE V1A RECEIVER; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND IN THE TREATMENT OF HYPERTENSION, DESMENO
PT1988914E (en) Combination of somatostatin-analogs with different selectivity for human somatostatin receptor subtypes
CL2007003503A1 (en) COMPOUNDS DERIVED FROM INDOL-2-IL-CARBONIL-PIPERIDINA-BENZOIMIDAZOLONA AND INDOL-2-IL-CARBONIL-PIPERIDINA-BENZOXAZOLONA, ANTAGONISTS OF THE V1A RECEIVER; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; AND USE FOR DISMENORREA TREATMENT

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08774848

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08774848

Country of ref document: EP

Kind code of ref document: A2